2007 Industry Financials, including 12 months of company financial data and
market caps for the US, Europe, Canada, and Asia
Analysis of key activities across industry sectors including healthcare,
personalized, predictive and, preventive medicine, wellness, ag-biotech,
industrial biotechnology and biofuels
Highlights of the most important recent advances in technology including
stem cells and nanotechnology
Politics and Policy - with special features on the presidential campaign
and how it is likely to affect the life sciences industry
Analysis of deal making, the venture capital environment and capital
markets.
The biotech industry around the world - Canada, Europe, Asia, with special
features on emerging global players such as China, India, Malaysia, Brazil
Table of Contents
Table of Contents
Chapter 1: 20/20 Vision to 2020
Our Vision
Healthcare
AgBio
The Global Scene
Business Models and Market Cap
Chapter 2: Industry Metrics
2007 Snapshot
The Capital Markets
Financings
M&A/Partnering
Regulatory
Biofuels in the Melting Pot
Global Biotech Crop Area Increased
International
Burrill' s Predictions for Biotech in 2008
Chapter 3: Healthcare
Pharma Readies for the Future
Modest Growth Predicted for Pharmaceutical Market
Mixed Year for Pharma and Biotech
Pharma' s Top-Selling Drugs Starting to Peak
Steady Growth for Biotech Drugs
Product Approvals
Selected Major Setbacks in 2007
Innovation Gap Still Wide
Healthcare Spending
Personalized Medicine
Investors Wowed by Personalized Medicine
Diagnostics Companies Have a Good Year
Companion Diagnostics
Reimbursement is Critical
Dx Attracts Venture Capital and Suitors
Chapter 4: Wellness
Consumers Want a Quality Experience
Big Food Goes Healthy
Wall Street Performance
M&A
Investors Whet Their Appetite
The International Market
The Regulatory Arena
Wellness and Prevention: The New Watchwords of Healthcare
Nutrigenomics Advances Personalized Nutrition
Healthy Aging
Using Beauty Drugs and Foods to Slow the Advance of Time
Organic Becomes Mainstream
Targeting Obesity
Biotech and Pharma Weigh In
Functional Foods for Weight Control
Edible Remedies
Medical Foods and Plant-based Therapies
Functional Foods
Probiotics: Focus on Digestive Health
Supplements
Looking Ahead
Chapter 5: Emerging Technologies
Technologies Impacting Healthcare
Systems Biology
From Sequences to Systems Biology
Systems Biology Alters Drug Development
Nanomedicine
Nanotubes
Nanowires
Nanodiagnostics
NIH Roadmap 2008
Human Microbiome Project
Epigenomics
The Quest for the $1,000 Genome
The X PRIZE
Human Whole-Genome Sequencing
Illumina Sequences Genome of African Male
Scientists Create First Synthetic Bacterial Genome
The Power of RNA
RNA Interference-Switching Genes Off
RNA Activation-Switching Genes On
microRNA-Great Potential in Diagnostics and Treatments
Gene Therapy
Genomics: Back on the Radar Screen
Chapter 6: Politics and Policy
FDA Amendments Act: Higher Fees, Enhanced Safety 118
PDUFA IV: Booming User Fees
Trials Registry and Databank
Conflict of Interest Waivers
What We Talk About When We Talk About Preemption
Post-Vioxx: The Need for Improved Drug Safety
FDAAA and Safety
Medical Device User Fee and Modernization Act
Changing Landscape 126
Diagnostics and Devices 128
Genomics: The Future of Safety?
The Genomics and Personalized Medicine Act of 2007
Personalized Medicine Milestone: Warfarin
IVDMIAs: FDA Revises Draft Guidance
MammaPrint: The First
Report Roundup: Genetics Tests and Nanotech Draw Scrutiny from Federal
Agencies
Other Device and Diagnostic News
Patents: Worrisome Patent Changes on the Horizon
In the Courts
New USPTO Rules
Patent Reform Legislation
Storm Warnings
Global Stem Cell Developments
Asia Moves Forward With Stem Cell Research
Other Stem Cell News
Asian Trends
An Overview of EU Developments
Chapter 7: Agbio
The Gene Revolution Transforms the Green Revolution
Companies Drive Innovation
Monsanto: A Long List of Deals
Syngenta Goes East-To China and Australia
Dow Goes South-To Latin America
DuPont: Busy Globally
Brazil: A Growing Player
Transgenics Become Mainstream
Global Metrics
Countries Move to Develop Own GM Technology
US Farmers Embrace Transgenics
Genetic Modification Taking Root in Europe-Slowly
The Changing Regulatory Landscape
Enabling Technologies
RNA Interference as a Pesticide
Bioremediation
Enhancing the Nutritional Quality of Food
Molecular Breeding, A Next-Generation Technology
Plant-Made Pharmaceuticals Become a Reality
Transgenic Animals
Looking Ahead
Chapter 8: Industrial Biotech and Biofuels
The New Bio-Economy
International Initiatives
The United States: the Energy Independence and Security Act of 2007
Corporate Developments
Companies Push into the Global Market
Oil Companies Get Green
Cleantech Fuels VC Interest
Alternative Energy Gets US Government Backing
Bioenergy
Ethanol
Cellulosic Ethanol/Biomass
Biodiesel
Algae: A Potential Next-Generation Feedstock
Using Synthetic Biology To Make Designer Microbes
Microbial Fuel Cells
Bioplastics
Integrated Biorefineries
Biochememicals
Looking Ahead
Chapter 9: International
Europe
Denmark
Canada
Australia/New Zealand
China
Japan
Malaysia
India
Chapter 10: M&A/Partnering
Activity Down
Select M&A Transactions
$5-Billion-plus Deals
$1-Billion-plus Deals
Specialty Sector Transactions
Cancer
Trends
Regional M&A
Partnering
Deal Activity
The Top 18
Regional Alliances
Analysis of Transactions
The Outlook to 2020
Chapter 11: Finance & Capital Markets
No Shortage of Capital for Biotechs
Positive Year for Biotech IPOs
China Connection
Other IPO Winners
On the Runway
PIPEs-An Essential Vehicle for Biotech
Follow-Ons
Debt
Venture Capital at Record Levels
Positive Performance on Capital Markets
Billion-Dollar Club
Burrill Mid-Cap Index
Burrill Small-Cap Index
Creative Financing and Listing Alternatives
Euronext
Biotech Platform
Looking Ahead
Industry Financial Data Reconciliation
Companies Ranked by December 31, 2007 Market Cap
Companies in Alphabetical Order
Chapter 12: About Burrill & Company
Burrill & Company
Venture Capital
International
Greater China Group
India Group
Japan Group
Latin America Group
Malaysia Group
Middle East Group
Advisory Boards
Large Corporate Limited Partners
Portfolio Companies
Private Equity
Merchant Banking
Media
Biotech 2008 - Life Sciences: A 20/20 Vision to 2020 published by BURRILL & COMPANY in April 19, 2008. This report price starts from US $ 295.
The contents of this page may be different from the latest version. Please contact us for details.
